Somatostatin receptor PET in neuroendocrine tumours: 68Ga- DOTA0,Tyr3-octreotide versus 68Ga-DOTA 0-lanreotide

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 40, Issue 3, 2013, Pages 364-372

  Putzer, Daniel ^a   Kroiss, Alexander ^a   Waitz, Dietmar ^a   Gabriel, Michael ^a   Traub Weidinger, Tatjana ^b   Uprimny, Christian ^a   Von Guggenberg, Elisabeth ^a   Decristoforo, Clemens ^a   Warwitz, Boris ^a   Widmann, Gerlig ^a   Virgolini, Irene Johanna ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Lanreotide PET; Neuroendocrine tumour imaging; Somatostatin receptor scintigraphy

Indexed keywords

LANREOTIDE TETRAXETAN GALLIUM GA 68; OCTREOTIDE TETRAXETAN GALLIUM GA 68; SOMATOSTATIN RECEPTOR; TETRAXETAN; UNCLASSIFIED DRUG; YTTRIUM 90;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HUMAN; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; POSITRON EMISSION TOMOGRAPHY; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RADIOTHERAPY; RETROSPECTIVE STUDY; SCINTIGRAPHY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; FEMALE; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PEPTIDES, CYCLIC; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; RETROSPECTIVE STUDIES; SOMATOSTATIN; YOUNG ADULT;

EID: 84873987152     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2286-6     Document Type: Article

References (33)

1. Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control 2011;18:127-37.
2. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836-46.
3. Froidevaux S, Eberle AN. Somatostatin analogs and radiopeptides in cancer therapy. Biopolymers 2002;66:161-83.
4. Reubi JC. Clinical relevance of somatostatin receptor imaging. Eur J Endocrinol 1994;131:575-6.
5. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010;17:R53-73.
6. Öberg KE, Reubi JC, Kwekkeboom DJ, Krenning EP. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology 2010;139:742-53.
7. Virgolini IJ, Szilvasi I, Kurtaran A, Angelberger P, Raderer M, Havlik E, et al. Indium-111-DOTA-lanreotide: biodistribution, safety and radiation absorbed dose in tumor patients. J Nucl Med 1998;39:1928-36.
8. Bombardieri E, Coliva A, Maccauro M, Seregni E, Orunesu E, Chiti A, et al. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals. Q J Nucl Med Mol Imaging 2010;54:3-15.
9. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20:716-31.
10. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-47.
11. Kaltsas GA, Papadogias G, Makras P, Grossman AB. Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues. Endocr Relat Cancer 2005;12:683-99.
12. Virgolini I, Traub T, Leimer M, Novotny C, Pangerl T, Ofluoglu S, et al. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Q J Nucl Med 2000;44:50-8.
13. Gabriel M, Andergassen U, Putzer D, Kroiss A, Waitz D, Von Guggenberg E, et al. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging 2010;54:92-9.
14. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24:389-427.
15. Putzer D, Gabriel M, Henninger B, Kendler D, Uprimny C, Dobrozemsky G, et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3- octreotide PET in comparison to CT and bone scintigraphy. J Nucl Med 2009;50:1214-21.
16. Gabriel M, Oberbauer A, Dobrozemsky G, Decristoforo C, Putzer D, Kendler D, et al. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy. J Nucl Med 2009;50:1427-34.
17. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 2007;48:508-18.
18. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007;34:1617-26.
19. Smith-Jones PM, Bischof C, Leimer M, Gludovacz D, Angelberger P, Pangerl T, et al. DOTA-lanreotide: a novel somatostatin analog for tumor diagnosis and therapy. Endocrinology 1999;140:5136-48.
20. Rodrigues M, Traub-Weidinger T, Leimer M, Li S, Andreae F, Angelberger P, et al. Value of 111In-DOTA-lanreotide and 111In-DOTA-DPhe1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2005;32:1144-51.
21. Rodrigues M, Traub-Weidinger T, Li S, Ibi B, Virgolini I. Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2006;33:532-40.
22. Virgolini I, Traub T, Novotny C, Leimer M, Füger B, Li SR, et al. New trends in peptide receptor ligands. Q J Nucl Med 2001;45:153-9.
23. Prasad V, Fetscher S, Baum RP. Changing role of somatostatin receptor targeted drugs in NET: nuclear medicine's view. J Pharm Pharm Sci 2007;10:321s-37s.
24. Traub-Weidinger T, Von Guggenberg E, Dobrozemsky G, Kendler D, Eisterer W, Bale R, et al. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography. Q J Nucl Med Mol Imaging 2010;54:52-60.
25. Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P. 111In- and 90Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med 2002;32:148-55.
26. Breeman WA, de Jong M, de Blois E, Bernard BT, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 2005;32:478-85.
27. Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol 2010;16:2963-70.
28. Savelli G, Lucignani G, Seregni E, Marchianò A, Serafini G, Aliberti G, et al. Feasibility of somatostatin receptor scintigraphy in the detection of occult primary gastro-entero-pancreatic (GEP) neuroendocrine tumours. Nucl Med Commun 2004;25:445-9.
29. Leimer M, Kurtaran A, Smith-Jones P, Raderer M, Havlik E, Angelberger P, et al. Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma. J Nucl Med 1998;39:2090-4.
30. Traub T, Petkov V, Ofluoglu S, Pangert T, Raderer M, Fueger BJ, et al. 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. J Nucl Med 2001;42:1309-15.
31. Kwekkeboom DJ, de Herder W, van Ejick CH, Kam BL, van Essen M, Teunissen JJ, et al. Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 2010;40:78-88.
32. Moncayo R. Reflections on the theory of "silver bullet" octreotide tracers: implications for ligand-receptor interactions in the age of peptides, heterodimers, receptor mosaics, truncated receptors, and multifractal analysis. EJNMMI Res 2011;1:9.
33. Fueger BJ, Hamilton G, Raderer M, Pangerl T, Traub T, Angelberger P, et al. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells. J Nucl Med 2001;42:1856-62.